Get the Stockscreener App
3.21
4.46%
-0.15
After Hours:
3.22
0.01
+0.31%
Lantern Pharma Inc stock is traded at $3.21, with a volume of 40,554.
It is down -4.46% in the last 24 hours and down -19.14% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.36
Open:
$3.28
24h Volume:
40,554
Relative Volume:
0.33
Market Cap:
$37.58M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-1.8034
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
-9.32%
1M Performance:
-19.14%
6M Performance:
-3.31%
1Y Performance:
+1.58%
1-Day Range:
$3.1579
$3.3865
1-Week Range:
$3.1579
$3.70
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.21 | 37.58M | 0 | -19.25M | -17.87M | -1.78 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Is Lantern Pharma Inc. stock vulnerable to regulatory risksJuly 2025 Technicals & High Accuracy Trade Signal Alerts - newser.com
Is Lantern Pharma Inc. stock oversold or undervaluedTrade Signal Summary & Risk Managed Investment Strategies - newser.com
How Lantern Pharma Inc. stock reacts to global recession fearsEarnings Overview Summary & Reliable Price Breakout Alerts - newser.com
How Lantern Pharma Inc. stock performs in weak economyQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Gadsden Times
Using economic indicators to assess Lantern Pharma Inc. potentialQuarterly Trade Report & Daily Stock Trend Reports - newser.com
Can Lantern Pharma Inc. stock deliver consistent earnings growthMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2025 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: Progress and Funding Needs - TipRanks
Lantern Pharma’s Q3 2025: Clinical and AI Progress - TipRanks
Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress - Digital Journal
Transcript : Lantern Pharma Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Will Lantern Pharma Inc. stock maintain dividend yieldBreakout Watch & Free Risk Controlled Daily Trade Plans - newser.com
LTRN: Pivotal quarter with clinical milestones, AI platform advances, and cash runway into Q3 2026 - TradingView
Earnings call transcript: Lantern Pharma Q3 2025 sees stock rise after earnings - Investing.com India
Lantern Pharma : Q3 2025 Earnings Call - MarketScreener
Lantern Pharma Achieves Key Milestones in Q3 2025 - TipRanks
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Full technical analysis of Lantern Pharma Inc. stock2025 Short Interest & Community Consensus Picks - newser.com
Lantern Pharma Earnings Preview - Benzinga
Lake Street Schedules Virtual Meeting for November 20 with LTRN Focus - GuruFocus
Lantern Pharma Q3 2025 Earnings Call Transcript - MarketBeat
How Lantern Pharma Inc. stock reacts to oil pricesMarket Risk Report & Daily Stock Momentum Reports - newser.com
Is Lantern Pharma Inc. stock a buy before product launchesJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE - Digital Journal
Lantern Pharma Inc. stock trendline breakdownEarnings Summary Report & Community Trade Idea Sharing - newser.com
Is Lantern Pharma Inc. stock attractive for income investorsWatch List & Stepwise Trade Signal Guides - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lancaster Eagle-Gazette
Lantern Pharma (LTRN) Partners with New to The Street for Extens - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):